

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Qianhai Health Holdings Limited

前海健康控股有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 911)

**(1) APPOINTMENT AND RESIGNATION OF EXECUTIVE DIRECTORS AND AUTHORISED REPRESENTATIVE AND
(2) NON-COMPLIANCE WITH LISTING RULES**

The Board is pleased to announce that Mr. Chen Li Kuang has been appointed as an executive Director with effect from 1 April 2022.

The Board further announces that Mr. Lam Hin Chi has tendered his resignation as an executive Director and the Authorised Representative with effect from 30 April 2022 due to his intention to pursue with his personal commitments.

Following to Mr. Lam Hin Chi's resignation, the Board also announces that Mr. Huang Guanchao has been appointed as the Authorised Representative with effect from 30 April 2022.

APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Qianhai Health Holdings Limited (the “**Company**”) is pleased to announce that Mr. Chen Li Kuang (“**Mr. Chen**”) has been appointed as an executive Director with effect from 1 April 2022.

Mr. Chen Li Kuang (陳立光)

The biographical details of Mr. Chen are set out below.

Mr. Chen, aged 46, has over 20 years of management experience in sales and distribution of electronic components and products. Mr. Chen had worked for several international technology companies in Taiwan and was primarily responsible for products management, marketing development and procurements. Mr. Chen graduated from the Jinwen University of Science and Technology with the Diploma in Bank and Insurance.

Mr. Chen has entered into a service contract with the Company, pursuant to which he was appointed as an executive Director for a term of three years commencing from 1 April 2022. Pursuant to the articles of association of the Company (the “**Articles**”), Mr. Chen will hold office until the next following general meeting of the Company and will be eligible for re-election at that meeting. His appointment is also subject to retirement by rotation and re-election at the annual general meeting in accordance with the provisions in the Articles. Pursuant to his service contract, Mr. Chen shall be entitled to a remuneration of HK\$600,600 per annum, which was determined with reference to his duties and responsibilities with the Company and the prevailing market conditions.

As at the date of this announcement, Mr. Chen (i) does not have, and is not deemed to have, any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders (as defined under the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”)) of the Company; (iii) did not hold any directorship in the last three years preceding the date of this announcement in any public companies the securities of which are listed on any securities market in Hong Kong or overseas; and (iv) does not have other major appointments and professional qualifications.

Save as disclosed above, there are no other matters that need to be brought to the attention of the shareholders of the Company in connection with the appointment of Mr. Chen as an executive Director and there is no other information that should be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to express its warm welcome to Mr. Chen on his appointment as an executive Director.

RESIGNATION OF DIRECTOR AND AUTHORISED REPRESENTATIVE

The Board announces that Mr. Lam Hin Chi (“**Mr. Lam**”) has tendered his resignation as an executive Director and the authorised representative of the Company (the “**Authorised Representative**”) under Listing Rules with effect from 30 April 2022 due to his intention to pursue with his personal commitments.

Mr. Lam confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board would like to express its appreciation to Mr. Lam for his contributions to the Company during his tenure of services in the Company.

APPOINTMENT OF AUTHORISED REPRESENTATIVE

The Board announces that Mr. Huang Guanchao, our non-executive Director, will be appointed as the Authorised Representative under Rule 3.05 of the Listing Rules to fill the vacancy arising from the resignation of Mr. Lam with effect from 30 April 2022.

NON-COMPLIANCE WITH RULE 3.10A LISTING RULES

Following the appointment of Mr. Chen as an executive Director and prior to the resignation of Mr. Lam as an executive Director becoming effective, the number of independent non-executive Directors falls short of the minimum number required under Rule 3.10A of the Listing Rules, which requires the number of independent non-executive directors representing at least one-third of the Board, between the period of 1 April 2022 to 30 April 2022.

The Board is of the view that following Mr. Lam’s resignation with effect from 30 April 2022, the Board will comprise nine members with two executive Directors, four non-executive Directors and three independent non-executive Directors. Accordingly, the Company shall then fulfill the minimum requirement prescribed in Rule 3.10A of the Listing Rules.

By order of the Board
Qianhai Health Holdings Limited
Huang Guanchao
Chairman

Hong Kong, 1 April 2022

As at the date of this announcement, the non-executive Directors are Mr. Huang Guanchao, Mr. Lim Tzea, Mr. Chen Kaiben and Mr. Chen Qi; the executive Directors are Mr. Xu Keli, Mr. Lam Hin Chi and Mr. Chen Li Kuang and the independent non-executive Directors are Mr. Li Wei, Mr. Yuen Chee Lap Carl and Mr. Leung Chun Tung.